Astera Labs Executive Plans to Sell 686 Shares on NASDAQ

A Form 144 filing for Astera Labs indicates a proposed sale of 686 shares of common stock with an aggregate market value of $60,368.

Rhea-AI Filing Summary

A Form 144 filing for Astera Labs indicates a proposed sale of 686 shares of common stock with an aggregate market value of $60,368. The sale is planned to be executed through UBS Financial Services on the NASDAQ exchange, with an approximate sale date of June 24, 2025.

The shares were acquired on June 23, 2025, through a Restricted Stock Unit (RSU) grant from the issuer. The current total shares outstanding for the company is 164,916,814.

Key details:

• Share price implied by filing: ~$88 per share
• Transaction represents approximately 0.0004% of total shares outstanding
• No other securities were sold by the filer during the past 3 months
• Sale will be executed on NASDAQ through UBS Financial Services

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of ALAB stock are being sold according to the Form 144 filing from June 2025?

According to the Form 144 filing, 686 shares of ALAB common stock are proposed to be sold through UBS Financial Services, Inc., with an aggregate market value of $60,368.00.

What is the total number of outstanding shares for ALAB as of June 2025?

According to the Form 144 filing, ALAB has 164,916,814 shares outstanding as of the filing date.

How were the ALAB shares acquired by the seller before the proposed sale?

The shares were acquired on June 23, 2025 through RSUs (Restricted Stock Units) from the issuer. The nature of payment is listed as 'N/A' since these were granted as equity compensation rather than purchased.

When is the approximate date of sale for the ALAB shares mentioned in the Form 144?

The approximate date of sale for the ALAB shares is listed as June 24, 2025, and they are to be sold on the NASDAQ exchange through UBS Financial Services, Inc.

Has the Form 144 filer sold any other ALAB shares in the past 3 months?

No, according to the filing section 'Securities Sold During The Past 3 Months,' there is nothing to report, indicating the filer has not sold any other ALAB shares during this period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:06 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001405693
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Astera Labs, Inc.
SEC File Number	001-41979
Address of Issuer	2345 NORTH FIRST STREET SAN JOSE CALIFORNIA 95131
Phone	408-242-7319
Name of Person for Whose Account the Securities are To Be Sold	Mayer Bethany
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	686	60368.00	164916814	06/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/23/2025	RSU	Issuer			686	06/23/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/24/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/25/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Bethany Mayer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)